Data will dictate value. That's why the timeline with the clinicals are so important. As the data comes in the value increases. Adjunct is a slam dunk but the data has to be achieved. I really believe everything will move upwards rapidly once there is certainty about a completion date for Adjunct. The value will then depend on how long the company and SH's hold out. Do they complete the PPIII Mono and the pull the trigger. That would be a complete different number. Let's just say it's in multiples of Billions in market cap.
News 
Market Data 
Discover 
AI
